Physician profile

David V Spurlin

Dermatology · Birmingham, MI

NPI 1679500573

$13,336.36

in general payments reported to CMS, 2019-2025

45 companies · $2,501 in 2025

The $2,501 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,147.30
Education$488.64

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Biotech, INC. $2,187.48 2019-2025 Tremfya, Simponi Aria, Stelara
Genzyme Corporation $1,627.77 2019-2025
Abbvie INC. $1,620.86 2019-2025 Rinvoq, Skyrizi, Botox
Regeneron Healthcare Solutions, INC. $1,257.88 2019-2025 Dupixent, Libtayo
Novartis Pharmaceuticals Corporation $695.40 2019-2025
Sun Pharmaceutical Industries INC. $669.55 2019-2025 Ilumya
Pfizer INC. $624.85 2019-2025
Amgen INC. $575.18 2019-2025 Otezla, Otezla
Galderma Laboratories, L.P. $374.42 2019-2025 Aklief, Nemluvio, Oracea
Leo Pharma INC. $371.08 2019-2025 Adbry, Anzupgo
Almirall LLC $356.55 2019-2025 Klisyri
Lilly USA, LLC $355.38 2019-2025 Taltz, Ebglyss, Olumiant
Ucb, INC. $288.13 2019-2023 Cimzia, Bimzelx
E.R. Squibb & Sons, L.L.C. $210.78 2022-2025 Sotyktu
Ortho Dermatologics, A Division of Bausch Health US, LLC $201.83 2019-2024 Jublia, Arazlo
Show all 45 companies
CompanyGeneral paymentsYearsTop products
Allergan, INC. $183.56 2019-2021
Journey Medical Corporation $167.73 2021-2023
Arcutis Biotherapeutics, INC. $164.48 2023-2025 Zoryve
Sanofi-Aventis U.S. LLC $159.02 2019-2022
Epi Health, LLC $137.99 2019-2022
Vyne Pharmaceuticals INC. $121.00 2020-2021
Biofrontera INC. $120.79 2019-2024 Ameluz, Xepi, Bf-Rhodoled
Kyowa Kirin, INC. $88.85 2023-2024 Poteligeo
Mayne Pharma Commercial LLC $87.65 2019-2023
Celgene Corporation $86.58 2019
Boehringer Ingelheim Pharmaceuticals, INC. $79.55 2022-2025 Spevigo
Incyte Corporation $68.02 2023-2025 Opzelura
Dermira, INC. $49.83 2019-2021
Prugen, INC. Pharmaceuticals $49.18 2019
Genentech USA, INC. $43.54 2020-2022
Sensus Healthcare, INC. $41.76 2019
Revance Therapeutics, INC. $38.84 2024 Daxxify
Verrica Pharmaceuticals INC. $32.85 2024 Ycanth
Merz North America, INC. $23.52 2019
Dermavant Sciences, INC. $23.14 2024 Vtama
Encore Dermatology INC. $17.72 2019
Dusa Pharmaceuticals, INC. $17.20 2019
Melinta Therapeutics, LLC $17.06 2019
Promius Pharma LLC $15.67 2019
Sandoz INC. $15.60 2021
Helsinn Therapeutics (U.S.), INC. $15.23 2023 Valchlor
Sebela Pharmaceuticals INC. $14.34 2020
Taro Pharmaceuticals USA, INC. $14.07 2019
Janssen Pharmaceuticals, INC $13.17 2025 Tremfya
Merck Sharp & Dohme LLC $11.28 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

David V Spurlin

$13,336.36

in general payments reported 2019-2025

Years
2019-2025
Top company
Janssen Biotech, INC.
Context
The $2,501 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).

https://glasscript.com/doctor/30795/david-v-spurlin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.